Distributed genetic architecture across the hippocampal formation implies common neuropathology across major brain disorders

Competing Interest Statement

OAA has received speaker's honorarium from Lundbeck and Sunovion, and is a consultant to HealthLytix. A.M.D. is a Founder of and holds equity in CorTechs Labs, Inc, and serves on its Scientific Advisory Board. The terms of this arrangement have been reviewed and approved by UCSD in accordance with its conflict of interest policies. Other authors report no conflicts.

Funding Statement

The authors were funded by the Research Council of Norway (TK: 276082. OAA: 213837, 223273, 248778, 273291, 262656, 229129, 283798, 311993. LTW: 204966, 249795, 273345), the South-Eastern Norway Regional Health Authority (OAA: 2013-123, 2017-112, 2019-108. LTW: 2014-097, 2015-073, 2016-083), Norwegian Health Association (SB: 22731), Stiftelsen Kristian Gerhard Jebsen, the European Research Council (LTW: ERCStG 802998), and an NVIDIA Corporation GPU Grant (TK). The funding bodies had no role in the analysis or interpretation of the data; the preparation, review or approval of the manuscript; nor in the decision to submit the manuscript for publication. This work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT-Department (USIT) and on resources provided by UNINETT Sigma2 - the National Infrastructure for High Performance Computing and Data Storage in Norway. The research has been conducted using the UK Biobank Resource (access code 27412) and using summary statistics for various brain disorders that partly included 23andMe data. We would like to thank the research participants and employees of UK Biobank, the 23andMe and the consortia contributing summary statistics for making this work possible.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The UK Biobank was approved by the National Health Service National Research Ethics Service (ref. 11/NW/0382).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes